For the year ending 2025-12-31, PYXS had -$4,051K decrease in cash & cash equivalents over the period. -$63,511K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenues-Royalty | 0 |
| Revenues | 13,858 |
| Cost of revenues | 2,388 |
| Clinical Product Candidates | 25,901 |
| Clinical Product Manufacturing | 19,694 |
| Personnel Related Expenses Excluding Stock Based Compensation | 15,711 |
| Stock Based Compensation | 3,156 |
| Depreciation And Amortization | 1,819 |
| Other | 7,415 |
| Total research and development expenses | 73,696 |
| Personnel Related Expenses Excluding Stock Based Compensation | 5,235 |
| Stock Based Compensation | 8,645 |
| Professional And Consultant Fees | 4,179 |
| Other | 4,135 |
| Total general and administrative expenses | 22,194 |
| Total costs and operating expenses | 98,278 |
| Other segment income | 6,185 |
| Income tax expense (benefit) | 1,386 |
| Net loss | -79,621 |
| Depreciation and amortization | 4,511 |
| Stock-based compensation | 11,801 |
| Non-cash operating lease expense | 824 |
| Accretion of discount on marketable debt securities | 2,960 |
| Prepaid expenses and other current assets | -261 |
| Accounts payable | 6,026 |
| Accrued expenses and other current liabilities | -2,823 |
| Operating lease liabilities | -1,450 |
| Other | 71 |
| Net cash used in operating activities | -63,502 |
| Redemption of marketable debt securities | 165,871 |
| Purchase of marketable debt securities | 107,005 |
| Purchase of property and equipment | 9 |
| Net cash provided by (used in) investing activities | 58,857 |
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of offering costs | 2 |
| Proceeds from issuance of common stock pursuant to atm program, net of offering costs | 0 |
| Tax withholding payments related to net settlement of restricted common stock | 148 |
| Proceeds from the exercise of stock options | 632 |
| Proceeds from issuance of common stock under espp | 108 |
| Net cash provided by financing activities | 594 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -4,051 |
| Cash, cash equivalents and restricted cash at beginning of year | 20,945 |
| Cash, cash equivalents and restricted cash at end of year | 16,894 |
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)